Innovative models to explore hepatic involvement in Prader-Willi syndrome

Category	Detail
Condition	Prader-Willi Syndrome
Key Mechanisms	Impaired lipid storage and oxidation capacity in adipocytes; intrinsic alterations in lipid handling and endocrine signaling.
Target Population	Individuals with Prader-Willi Syndrome, affecting approximately 1 in 21,000 live births.
Care Setting	Clinical and metabolic assessment in neurodevelopmental disorders.

PWS is characterized by severe neonatal hypotonia and progressive hyperphagia leading to obesity.
Endocrinopathies include hypogonadotropic hypogonadism and growth hormone dysfunction.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is less prevalent in PWS.
PWS patients exhibit higher fat mass and lower fat-free mass compared to non-syndromic obesity.
Early diagnosis and supervision have improved life expectancy but mortality remains higher than in the general population.

Diagnosis is based on clinical features and genetic testing for PWS-related mutations.

Management includes behavioral interventions and monitoring of metabolic complications.

Regular assessment of weight, metabolic parameters, and associated comorbidities.

Increased risk of obesity-related complications such as type 2 diabetes and cardiovascular diseases.

Individuals diagnosed with Prader-Willi Syndrome.

Focus on managing obesity and associated metabolic disorders through dietary and behavioral strategies.

Implement early dietary restrictions to manage hyperphagia.
Monitor for endocrine abnormalities and metabolic complications regularly.
Utilize iPSC-derived models for research into liver dysfunction and metabolic mechanisms.

Clinical Scorecard: Novel Approaches to Investigate Liver Dysfunction in Prader-Willi Syndrome